

**Half-year statement of IPSEN Liquidity Providing agreement with NATIXIS  
and Transfer of this agreement to ODDO BHF**

Boulogne-Billancourt (France), July 19, 2018 – IPSEN announces that, following the effective implementation of the long-term partnership of NATIXIS with ODDO-BHF, its Liquidity Providing agreement initially entrusted to NATIXIS has been transferred to ODDO BHF.

At the termination of the Liquidity Providing Agreement signed between IPSEN and NATIXIS, the following resources were held by the liquidity account as of June 29th, 2018:

- 12,751 IPSEN shares
- €3,137,934.80

As a reminder, as of the last statement on this agreement, December 29th, 2017, the following assets were allocated to the liquidity account:

- 19,647 IPSEN shares
- €2,460,476.16

IPSEN has entrusted ODDO BHF and NATIXIS, and for a period of one year, automatically renewable, with the implementation of a liquidity agreement and its market watch in accordance with the Charter of Ethics established by the AMAFI and approved by the decision of the Autorité des Marchés Financiers on March 21st, 2011.

For the implementation of this agreement, the following resources were allocated to ODDO BHF for the liquidity account:

- 12,751 IPSEN shares
- €3,137,934.80

**About Ipsen**

Ipsen is a global biopharmaceutical company focused on innovation and specialty care. The group develops and commercializes innovative medicines in three key therapeutic areas - Oncology, Neurosciences and Rare Diseases. Its commitment to oncology is exemplified through its growing portfolio of key therapies for prostate cancer, neuroendocrine tumors, renal cell carcinoma and pancreatic cancer. Ipsen also has a well-established Consumer Healthcare business. With total sales over €1.9 billion in 2017, Ipsen sells more than 20 drugs in over 115 countries, with a direct commercial presence in more than 30 countries. Ipsen's R&D is focused on its innovative and differentiated technological platforms located in the heart of the leading biotechnological and life sciences hubs (Paris-Saclay, France; Oxford, UK; Cambridge, US). The Group has about 5,400 employees worldwide. Ipsen is listed in Paris (Euronext: IPN) and in the United States through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information on Ipsen, visit [www.ipсен.com](http://www.ipсен.com)

**For further information:****Media****Ian Weatherhead**

Vice President, Corporate External Communications

+44 (0) 1753 627733

[ian.weatherhead@ipsen.com](mailto:ian.weatherhead@ipsen.com)

**Financial Community****Eugenia Litz**

Vice President, Investor Relations

+44 (0) 1753 627721

[eugenia.litz@ipsen.com](mailto:eugenia.litz@ipsen.com)

**Myriam Koutchinsky**

Investor Relations Manager

+33 (0)1 58 33 51 04

[myriam.koutchinsky@ipsen.com](mailto:myriam.koutchinsky@ipsen.com)